Figure 5.

806 CAR T activity in heterogeneous GBOs highlights cross-reactivity of 806 binder against oncogenic EGFRs. CAR T coculture with GBOs was used to demonstrate anti-EGFR activity. (A) EGFR alterations identified in each GBO line. (B) Immunofluorescence images of CAR T cells engrafted GBOs, for four organoids per condition, 9057 (left) and 9066 (right). Blue = DAPI; red = CD3⁺; white = cleaved caspase 3⁺ (CC3⁺), scale bar = 100 µm. (C) Quantification of CD3⁺ cells (left) and CC3⁺ cells (right) showing antitumor activity from the 806 CAR T cells. (D) Immunofluorescence images of CAR T cell targets in GBOs, for 9057 (left) and 9066 (right). Blue = DAPI; red = EGFR⁺; white = EGFRvIII⁺, scale bar = 100 µm. (E) Quantification of EGFR⁺ (left) and EGFRvIII⁺ signals (right) showing antitumor activity from the 806 CAR T cells. Error bars are ± standard error. ns, p > 0.05.